EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Clinical and experimental treatment of advanced melanoma with a focus on immunotherapy

Lucy Millar, Rafael Di Marco Barros, Matthaios Kapiris, Christos Nikolaou, Marco Gerlinger, Yin Wu iD

Clinical and Experimental Immunology · 2025

DOI: 10.1093/cei/uxaf073 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Experimental Immunology, 2025. Verfasst von Lucy Millar und 5 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Inflammation Biology and Cancer Immunology, King's College London, London, UK. Hauptthemen laut MEDLINE: Melanoma, Immunotherapy, Immune Checkpoint Inhibitors, Skin Neoplasms. Die Arbeit nennt 139 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, CRUK City of London Centre Clinical Academic Training Programme - Cohort 2024, Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Melanoma is currently the fifth most common cancer in the UK, and its incidence is rising. Although surgery is curative for many early-stage tumours, advanced disease which is inoperable has historically also been considered incurable. Recent and rapid advances in cancer immunotherapy, particularly immune checkpoint inhibitors, have now revolutionized the management of advanced melanoma with many patients likely being cured. Here, we review the immunobiology of melanoma, the growing list of standard-of-care immunotherapies and the considerations around which treatment regimen to use. We also review evidence from recent clinical trials of promising novel immunotherapies which will hopefully help patients who do not benefit from current treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaImmunotherapyImmune Checkpoint InhibitorsSkin NeoplasmsHumansClinical Trials as TopicAnimals

Stichwörter der Autor:innen

Cancer ImmunologyImmune Checkpoint InhibitorsImmunotherapyMelanoma

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Centre for Inflammation Biology and Cancer Immunology, King's College London, London, UK.
  • Barts Cancer Institute, Queen Mary University of London, London, UK.
  • Department of Oncology, Guy's Hospital, London, UK.
  • Comprehensive Cancer Centre, King's College London, London, UK.
  • 4th Oncology Clinic, Henry Dunant Hospital, Athens, Greece.

ORCID-Profile: Yin Wu

Förderung

  • Wellcome Trust
  • CRUK City of London Centre Clinical Academic Training Programme - Cohort 2024
  • Cancer Research UK

Zitieren

APA

Millar, L., Di Marco Barros, R., Kapiris, M., Nikolaou, C., Gerlinger, M., & Wu, Y. (2025). Clinical and experimental treatment of advanced melanoma with a focus on immunotherapy. Clinical and Experimental Immunology. https://doi.org/10.1093/cei/uxaf073

Vancouver

Millar L, Di Marco Barros R, Kapiris M, Nikolaou C, Gerlinger M, Wu Y. Clinical and experimental treatment of advanced melanoma with a focus on immunotherapy. Clinical and Experimental Immunology. 2025. doi:10.1093/cei/uxaf073

BibTeX
@article{Millar2025,
  author = {Millar, Lucy and Di Marco Barros, Rafael and Kapiris, Matthaios and Nikolaou, Christos and Gerlinger, Marco and Wu, Yin},
  title = {Clinical and experimental treatment of advanced melanoma with a focus on immunotherapy},
  journal = {Clinical and Experimental Immunology},
  year = {2025},
  doi = {10.1093/cei/uxaf073}
}
Kostenlos starten →